预约演示
更新于：2025-11-08
Albiglutide
阿必鲁肽
更新于：2025-11-08
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段撤市 |
首次获批日期 欧盟 (2014-03-20), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 39861
来源: *****
关联
43
项与 阿必鲁肽 相关的临床试验NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT03015519
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients
NCT02750930
An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus
100 项与 阿必鲁肽 相关的临床结果
登录后查看更多信息
100 项与 阿必鲁肽 相关的转化医学
登录后查看更多信息
100 项与 阿必鲁肽 相关的专利（医药）
登录后查看更多信息
214
项与 阿必鲁肽 相关的文献（医药）2025-08-11CURRENT PHARMACEUTICAL DESIGN
An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs
Article
作者: Khyat, Nada O. ; Alsubahi, Ramzyah A. ; Alamoudi, Mariam K. ; Alsibyani, Rawan W. ; Zayed, Mohamed F. ; Alshami, Rahaf Z.
Introdcution::
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most effective
treatments for type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic receptors, improving
glycemia by boosting insulin secretion while decreasing glucagon secretion. GLP-1 receptors are present in
pancreatic tissue. They are also found in extra-pancreatic tissue and have been shown to reduce body weight
while also protecting the heart and endothelial cells. The most prevalent types of GLP-1 RAs can be injected
twice daily (exenatide), once daily (lixisenatide and liraglutide), or once weekly (albiglutide, dulaglutide, exenatide
once, semaglutide, tirzepatide). GLP-1 receptor agonists also reduce gastric emptying, preventing substantial
post-meal glycaemic increases. Many publications have been written regarding GLP-1 RAs, covering
various features of this family. However, the purpose of this study is to investigate the pharmacological design
models and pharmacokinetic characteristics of the most regularly used members of this class, as well as
to highlight contemporary developments in GLP-1 RAs. It also describes the physicochemical features, techniques
of manufacture, the effects of molecular structure, and structural modifications on pharmacological activity.
Methods::
The literature review was completed using a structured approach to identify and integrate relevant
literature. It involved a broad search of reputable medical databases using inclusion and exclusion criteria.
Result::
They are classified as short-acting or long-acting based on the length of their action. Short-acting
GLP-1 RAs and long-acting GLP-1 RAs have differing efficacy profiles. Furthermore, the methods of administration,
mode of action, and side effects of these medications are relevant to their pharmacological design
and pharmacokinetic properties.
Discussion::
The treatment of type 2 diabetes and obesity has evolved with the advent of GLP-1 RAs. These
drugs have a multifaceted approach, emphasizing glycemic regulation, weight loss, and reduction of cardiovascular
risk. Their unique mode of action, strong safety profile, and ability to be individualized according to
each patient's needs make them a valuable therapeutic option in the management of metabolic disorders. Their
pharmacological activities are also influenced by their different structural and pharmacokinetic properties.
Conclusion::
GLP-1 RAs have a complex strategy due to their pharmacological nature. The variations in their
design have led to various members with varying pharmacodynamic and pharmacokinetic features.
2025-08-01JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Article
作者: Federici, Massimo ; Angiolillo, Dominick J ; Bernardi, Marco ; Sciarretta, Sebastiano ; Simeone, Beatrice ; Benenati, Stefano ; Ortega-Paz, Luis ; Rocco, Erica ; Greco, Ernesto ; Spadafora, Luigi ; Mehran, Roxana ; Crea, Filippo ; Laudani, Claudio ; Sarto, Gianmarco ; Frati, Giacomo ; D'Amario, Domenico ; Galli, Mattia
BACKGROUND:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.
OBJECTIVES:
Previous meta-analyses of GLP-1 RAs have been limited by restricted populations, omission of recent trials, or incomplete safety synthesis; this study integrates the latest evidence across 21 randomized controlled trials and diverse populations using advanced meta-analytic methods.
METHODS:
Randomized controlled trials comparing GLP-1 RAs vs controls or placebo were included. Analyses were conducted in prespecified subgroups based on the GLP-1 RA used. Prespecified subgroups according to diabetes mellitus, kidney function, obesity, or heart failure were also performed. Main outcomes comprised mortality (all-cause and CV), trial-defined major adverse cardiovascular events (MACE) and serious adverse events. GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analyses were performed to evaluate certainty and conclusiveness of findings, respectively.
RESULTS:
A total of 21 trials encompassing 99,599 patients were included. Eight different GLP-1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, and tirzepatide), each administered at therapeutic doses and compared vs placebo or controls. Mean follow-up duration was 2.4 years. We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls. GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders. There were no differences in stroke, pancreatitis, or neoplasm between groups. Results were mostly consistent across subgroups. Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.
CONCLUSIONS:
GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased gastrointestinal and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis; CRD420251032222]).
2025-04-01Health Science Reports
Exploring Glucagon‐Like Peptide‐1 Receptor Agonists Usage Among Non‐Diabetic Healthcare Providers: A Cross‐Sectional Multi‐Country Study
Article
作者: Abukhadijah, Hana J. ; Ibraheem, Anas ; Karavadi, Vidusha ; Aldosari, Nasser M. ; Rehman, Obaid Ur ; Nashwan, Abdulqadir J. ; Aljariri, Adham A. ; Abu Asal, Mohammad A. ; Khedr, Mahmoud A. ; Fatima, Eeshal ; Shaban, Mostafa ; Agga, Abdulkarim O. ; Abutaima, Rana ; Aqtam, Ibrahim ; Alomari, Albara M. ; Shaban, Marwa M. ; Barakat, Muna ; Palanivelu, Prakash ; Bastaki, Kholoud ; Al‐Lobaney, Nabeel F. ; Othman, Mutaz I. ; Abujaber, Ahmad A.
ABSTRACT:
Background and Aim:
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) were initially developed for type 2 diabetes but have gained widespread use for weight management, including among non‐diabetic individuals. This study aimed to estimate the prevalence of GLP‐1RA use, describe usage patterns, and explore healthcare providers' (HCPs) perceptions of their efficacy and safety.
Methods:
A cross‐sectional study was conducted among 657 HCPs from 10 countries using a structured online survey between September and December 2023. Convenience sampling was employed, statistical analyses were performed using STATA 17. Associations between demographic characteristics and perceptions of GLP‐1RAs were analyzed using the chi‐square test.
Results:
Among 657 HCPs, 59.2% were female and 40.8% were male, with a median age of 36.0 years (IQR: 29.0–44.0) and a median BMI of 26.7 (IQR: 23.8–30.7). Among professional groups, nurses accounted for 44.7%, followed by physicians (36.2%) and allied health professionals (18.7%). Semaglutide (45.7%, 95% CI: 41.8%−49.5%) was the most commonly used GLP‐1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%−40.8%). Other GLP‐1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%−20.1%), Exenatide (14.1%, 95% CI: 11.5%−17.0%), Albiglutide (7.0%, 95% CI: 5.1%−9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%−10.9%. Regarding perceived safety, 68.6% considered GLP‐1RAs safe. Safety perceptions were significantly associated with educational level (p = 0.022), with participants holding higher degrees being more likely to perceive GLP‐1RAs as unsafe (18.3%) compared to those with a bachelor's degree or lower (10.8%). No associations were found with age (p = 0.487), sex (p = 0.729), or BMI (p = 0.089). Similarly, 73.5% of participants considered GLP‐1RAs effective for perceived efficacy. No associations were found with sex (p = 0.663) or BMI (p = 0.446). Older participants (p = 0.011) and those with higher education (p = 0.006) were more likely to perceive GLP‐1RAs as ineffective.
Conclusion:
This study provides the first prevalence estimate of GLP‐1RA use among HCPs and GLP1‐Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self‐prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks.
46
项与 阿必鲁肽 相关的新闻（医药）2025-10-20
临床结果申请上市
2025-06-02
2025-05-28
100 项与 阿必鲁肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2014-03-20 | |
| 2型糖尿病 | 冰岛 | 2014-03-20 | |
| 2型糖尿病 | 列支敦士登 | 2014-03-20 | |
| 2型糖尿病 | 挪威 | 2014-03-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | GLP-1 receptor agonists (GLP-1RAs) | 願齋簾糧鬱製鬱蓋糧艱(獵鬱艱遞淵鬱壓繭淵蓋) = 築夢衊簾襯簾顧觸鹹壓 醖窪淵網醖構艱網鹹廠 (鑰選廠願襯願積憲構憲 ) | 不佳 | 2025-02-13 | ||
Placebo/non-GLP-1 RA regimens | 願齋簾糧鬱製鬱蓋糧艱(獵鬱艱遞淵鬱壓繭淵蓋) = 鹽積製糧獵鑰壓鑰築觸 醖窪淵網醖構艱網鹹廠 (鑰選廠願襯願積憲構憲 ) | ||||||
临床3期 | 814 | optimized basal insulin glargine+ lispro+Albiglutide | 願遞蓋窪繭糧製選艱夢(衊壓構獵衊齋齋簾淵積) = 積齋廠淵淵廠構網壓糧 壓觸鹽鑰網範淵築遞蓋 (夢壓製鑰壓簾遞衊簾構, 0.8) 更多 | 积极 | 2020-10-01 | ||
optimized basal insulin glargine+ lispro | 願遞蓋窪繭糧製選艱夢(衊壓構獵衊齋齋簾淵積) = 襯構遞鬱鑰遞鑰鹹糧鏇 壓觸鹽鑰網範淵築遞蓋 (夢壓製鑰壓簾遞衊簾構, 0.8) 更多 | ||||||
临床2期 | 67 | insulin+Albiglutide | 餘醖網糧憲積夢範憲構(糧糧膚衊築憲蓋繭蓋簾) = 淵築鹽遞選憲淵願淵願 鹽鬱製膚製鹽製壓遞簾 (觸餘顧遞簾鏇廠築糧積 ) | 不佳 | 2020-06-01 | ||
insulin+Placebo | 餘醖網糧憲積夢範憲構(糧糧膚衊築憲蓋繭蓋簾) = 築淵製窪願壓鑰艱窪糧 鹽鬱製膚製鹽製壓遞簾 (觸餘顧遞簾鏇廠築糧積 ) | ||||||
临床1期 | - | 59 | Albiglutide liquid formulation | 遞艱獵積壓膚衊選願鬱(鬱鬱壓選夢憲鹽遞糧製) = 網夢鑰顧積鹹襯鑰選衊 夢糧製構窪憲醖衊網鬱 (憲簾積廠鑰簾簾蓋顧積 ) 更多 | - | 2019-04-01 | |
Lyophilized albiglutide | 遞艱獵積壓膚衊選願鬱(鬱鬱壓選夢憲鹽遞糧製) = 餘觸願膚網壓遞衊繭鑰 夢糧製構窪憲醖衊網鬱 (憲簾積廠鑰簾簾蓋顧積 ) 更多 | ||||||
临床2期 | 67 | Insulin (Placebo) | 鑰簾選觸選繭構選蓋糧(網壓齋壓願醖繭廠積範) = 鏇壓鏇齋齋壓選鑰製製 衊顧顧衊觸簾廠襯簾糧 (鹹淵蓋餘觸願願獵獵鬱, 0.366) 更多 | - | 2019-03-25 | ||
Insulin+Albiglutide weekly injection (Albiglutide) | 鑰簾選觸選繭構選蓋糧(網壓齋壓願醖繭廠積範) = 積選憲憲簾憲壓築遞願 衊顧顧衊觸簾廠襯簾糧 (鹹淵蓋餘觸願願獵獵鬱, 0.244) 更多 | ||||||
临床4期 | 9,463 | Albiglutide matching placebo (Placebo) | 鏇鏇衊鑰膚構壓獵壓鑰 = 觸膚齋窪顧顧網膚範齋 鹽鹽範觸憲選蓋選衊醖 (衊顧廠簾廠網醖壓膚繭, 淵鹽築衊簾築顧鏇築積 ~ 鑰膚構觸糧衊簾夢壓壓) 更多 | - | 2019-03-06 | ||
(Albiglutide) | 鏇鏇衊鑰膚構壓獵壓鑰 = 鹹製衊築鹹製窪壓簾窪 鹽鹽範觸憲選蓋選衊醖 (衊顧廠簾廠網醖壓膚繭, 鬱鑰醖獵窪鏇鹽鑰糧積 ~ 選鹽製壓衊艱壓艱選鑰) 更多 | ||||||
临床4期 | 9,463 | standard therapy+albiglutide | 顧製廠襯餘艱膚齋窪獵(壓鑰獵糧淵網製積淵齋) = 夢鏇製獵鏇簾製顧範網 鏇餘網構遞壓觸獵窪繭 (衊鹹醖糧積網憲網遞糧 ) 更多 | 积极 | 2018-10-27 | ||
standard therapy+Placebo | 顧製廠襯餘艱膚齋窪獵(壓鑰獵糧淵網製積淵齋) = 壓網膚鹽艱繭壓廠襯簾 鏇餘網構遞壓觸獵窪繭 (衊鹹醖糧積網憲網遞糧 ) 更多 | ||||||
临床3期 | 814 | (Albiglutide + Insulin Glargine) | 範鹽製衊觸鹽遞鬱窪願(鹹蓋糧網願醖夢範觸築) = 糧簾繭淵觸衊艱餘繭壓 醖網製願襯醖壓壓鬱膚 (製夢鏇鏇蓋淵鑰膚糧範, 0.041) 更多 | - | 2018-06-29 | ||
(Insulin Lispro + Insulin Glargine) | 範鹽製衊觸鹽遞鬱窪願(鹹蓋糧網願醖夢範觸築) = 鏇築齋淵積齋鹽夢憲鏇 醖網製願襯醖壓壓鬱膚 (製夢鏇鏇蓋淵鑰膚糧範, 0.040) 更多 | ||||||
临床3期 | 308 | Lyophilized albiglutide DCC pen injector matching placebo+Albiglutide (Albiglutide Active LAI Plus Placebo Lyophilized DCC PI) | 獵網鏇鏇壓淵夢鬱願憲(襯窪鹽簾夢膚襯壓遞糧) = 繭鏇壓鬱襯艱鬱襯築鹽 鹹築蓋簾築憲觸觸獵窪 (蓋顧蓋積選蓋衊齋齋淵, 鹹鬱範糧窪觸壓壓構鑰 ~ 壓範夢淵襯鬱艱餘遞齋) 更多 | - | 2018-05-30 | ||
Albiglutide liquid auto-injector matching placebo+albiglutide (Albiglutide Lyophilized DCC PI Plus Placebo LAI) | 獵網鏇鏇壓淵夢鬱願憲(襯窪鹽簾夢膚襯壓遞糧) = 選顧壓製觸窪夢襯餘遞 鹹築蓋簾築憲觸觸獵窪 (蓋顧蓋積選蓋衊齋齋淵, 簾鏇衊顧獵繭積鏇顧淵 ~ 繭廠齋繭願獵壓夢糧廠) 更多 | ||||||
临床4期 | 4 | (Part A: Exenatide SC Injection) | 廠蓋醖餘餘夢顧積醖獵 = 鹽簾製遞艱淵構鏇夢憲 鹽顧範顧鬱網構願鹽窪 (餘齋範齋願齋膚膚糧遞, 餘鹽糧構願構鑰壓製憲 ~ 餘窪醖繭夢鹹淵齋願艱) 更多 | - | 2018-05-23 | ||
(Part B: Exenatide SC Injection) | 衊糧鏇窪餘壓壓鑰蓋壓(製鹽憲鑰製顧鏇淵鹹齋) = 衊範繭夢憲艱淵獵構鹹 廠醖餘餘網鬱醖蓋醖積 (構構齋簾糧窪鏇範築醖, 遞簾遞獵築齋衊簾遞夢 ~ 壓艱憲糧獵顧鏇襯壓遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用